Shorter Course Tacrolimus After Nonmyeloablative, Related Donor BMT With High-dose Posttransplantation Cyclophosphamide
Non Hodgkin's Lymphoma
Procedure: Bone Marrow Transplant
|Study Design:||Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Shortened-duration Tacrolimus Following Nonmyeloablative, Related Donor BMT With High-dose Posttransplantation Cyclophosphamide|
- Evaluate the safety of reduced-duration tacrolimus (from Day 5 through either To estimate the number of patients with GVHD as a measure of the safety of reduced-duration tacrolimus [ Time Frame: Day 5 - Day 120 ] [ Designated as safety issue: Yes ]Immunosuppression must be sufficient to prevent excessive rates of GVHD including severe GVHD. There are presently no published data on the minimum required duration of tacrolimus after nonmyeloablative, partially HLA-mismatched BMT that includes high-dose Cy as part of postgrafting immunosuppression.
- To estimate the tolerability of reduced-duration tacrolimus on patients following nonmyeloablative transplant. [ Time Frame: Day 60 - Day 180 ] [ Designated as safety issue: No ]Tacrolimus levels will be monitored. Patients who develop a prohibitive toxicity to tacrolimus (resulting in earlier than scheduled discontinuation of tacrolimus) will be considered unevaluable for the primary endpoint. The duration of tacrolimus will be evaluated at Day 90. If tacrolimus at Day 90 appears feasible, then it will be continued until Day 120 with analogous monitoring rules.
- Incidence of GVHD [ Time Frame: Day 180, and beyond Day 180 (up to 7 years) ] [ Designated as safety issue: Yes ]Estimate the incidences of acute grade II-IV GVHD, acute grade III or higher GVHD, chronic GVHD, graft failure, relapse, and nonrelapse mortality between the date of early tacrolimus cessation and Day 180, and beyond Day 180.
|Study Start Date:||July 2011|
|Estimated Study Completion Date:||June 2022|
|Estimated Primary Completion Date:||June 2018 (Final data collection date for primary outcome measure)|
Procedure: Bone Marrow Transplant
- High-dose Cy
The main goal is to learn whether a drug called tacrolimus, which is an immune-lowering drug (an immunosuppressant) given after transplant to help prevent certain complications, can be given safely for a shorter period of time than it has been in the past.
At the present time there are few or no cures for your type of disease outside of a bone marrow transplant. The bone marrow for this transplant comes from a relative who is a half-match or "haplo" match to you. Possible donors include parents, siblings, and children. In order to help the bone marrow grow, or "take", inside your body, you will receive chemotherapy and radiation before the transplant. After the transplant you will receive high doses of cyclophosphamide (Cytoxan®) along with other medications to lower the immune system, tacrolimus. These medications may lower the risk of graft versus host disease (GVHD) and of your body rejecting the bone marrow graft.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01342289
|Contact: Richard Jones, M.D.||email@example.com|
|United States, Maryland|
|Sidney Kimmel Comprehensive Cancer Center||Recruiting|
|Baltimore, Maryland, United States, 21231|
|Contact: Richard Jones, M.D. 443-287-7104 firstname.lastname@example.org|
|Principal Investigator:||Richard Jones, M.D.||Johns Hopkins University|